Exhibit 10.2

Amended supplementary agreement between CBH and Suzhou Erye
--------------------------------------------------------------------------------
This  amendment  (the  "Amendment")  to the  Agreement  signed among the parties
hereto on June 11, 2005 is signed in Suzhou City,  Jiangsu Province of China, on
August 3, 2005 by the following parties:

      Party A:  38 persons including and represented by SHI Ming Sheng & other
      Mailing address: No.859, Panxu Road, Canglang District, Suzhou City, China
      Tel: 86-512-68207173
      Fax : 86-512-68202801
      Legal representative: Shi Ming Sheng
      Nationality: China
      Party B: China Biopharmaceuticals Holdings Inc.
      Address: Suite 2005, 156 West 56th St., New York 10019, USA
      Tel (pound)(0)917-650-9201
      Fax (pound)(0)212-3101682
      Legal representative: Peng Mao
      Nationality: Canada
      Position: CEO

      Whereas:

      (1)  Party A  (consisting  of 38  persons)  is all the  shareholders  (For
details of  shareholders,  please see attached List of  Shareholders)  of Suzhou
Erye Pharmaceutical Limited Company (Referred to as "Erye" hereafter), a legally
registered  limited liability company  established  according to the laws of the
People's Republic of China ("China") laws, who authorizes its representative Shi
Mingsheng to represent all the shareholders to sign this agreement (For details,
please see the Trust Deed);  Party B is a legally  registered  limited liability
company according to Delaware Law of the United States of America ("U.S.A.").

      (2) In Accordance with The Company Law of China, The Contract Law of China
as well as  other  prevailing  laws  and  regulations,  Part B  decides  to make
investment in Erye, and Erye will become a foreign-invested company according to
Chinese laws (Referred to as the "Joint Venture"  hereafter).  Both parties have
signed the Merger Agreement.




<PAGE>

      (3) This  cooperation  between two parties refers to the issues  regarding
the operation and development of the joint venture; therefore, for the remaining
issues that are not fully  provided for in detail in the Merger  Agreement,  the
both parties make this agreement with amended supplementary provisions.

      Now therefore:

      1.    The Agreement is hereby  amended to reflect the  following  changes.
            This Amendment shall govern in case of conflicting interpretation on
            the Agreement.
      2.    Article 4.1 of the Agreement shall be amended as follows:  the board
            of directors of the Joint Venture shall consist of seven  directors,
            three  of whom to be  appointed  by  Party A and  four of whom to be
            appointed  by Party B.  Among the  directors  appointed  by Party B,
            Party B shall select one person from the current  management team of
            Erye. Party B agrees that Mr. SHI Mingsheng shall be the chairman of
            the first and second term of the board. All the directors  appointed
            by  Party  B  shall  be  responsible  to  Party  B and  act  at  the
            instruction  of  Party  B on  the  board  of  directors.
            Among  the  directors  appointed  by Party  A, one of whom  shall be
            recommended to act as director of Party B subject to the approval of
            Party  B's  shareholders.  If  this  director  fails  to be  elected
            director of board of party B, then this  director  shall have rights
            to audit the meeting of board of the  directors,  enjoying the right
            to full  knowledge  of the  operation  of the party B subject to the
            duty  of  confidentiality.  The  Chairman  of  the  board  shall  be
            appointed  by party  A, and the  chief  financial  officer  shall be
            appointed  by  party B  subject  to the  approval  of the  board  of
            directors.
            When the Joint Venture is initially  set up, Shi  Mingsheng  will be
            the Chairman of the board of the Joint Venture.  Meanwhile,  Party B
            shall  recommend to its  shareholders  that Shi  Mingsheng  hold the
            position of director of board of Party B.


<PAGE>

      3.    In terms of Article 4.2 of the Agreement,  on item shall be added to
            the important  events "Party B's transfer all or parts of its shares
            in the Joint Venture."
      4.    Article 8, the  Agreement  shall be  amended  to state:  "If Party B
            shall not be listed on the  NASD-Over  the  Counter  Bulletin  Board
            Market  in a  reasonable  time;  all the  assets,  stocks  and  cash
            exchanged shall be reverted back to the original parties."
      5.    Others

      5.1   For issues  that fail to be  mentioned  in this  Amendment,  the two
            parties may sign supplementary agreement or attachment,  which forms
            effective components of this Amendment with the same legal effect.

      5.2   This  Amendment  is in  quadruplicate,  with two copies held by each
            party.

      Party A: 38 persons including and represented by Shi Mingsheng

      Authorized representative: /s/ Shi Mingsheng
                                 Shi Mingsheng

      Party   B(pound)(0)China   Biopharmaceuticals   Holdings  Inc.

      Authorized representative: /s/ Peng Mao
                                 Peng Mao, Chief Executive Officer